Cynata Therapeutics Ltd V.CYP

Primary Symbol: CYYNF

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

OTCPK:CYYNF - Post by User

Cynata Therapeutics Ltd

Bullboard Posts

Post by GarryJan1on Jan 12, 2020 2:02pm

182 Views

Post# 30544110

Answer from Don re questions.

Hi Garry,

Good to hear from you. No, Cypress does not currently have water rights in Nevada but something we have been working on. I believe Willoughby said REE’s would be included in PFS previously but will check again and get back to you. I know there is lots of back and forth right now between Willoughby and Ausenco as PFS nears completion. We still have to wait for recent test work to complete, to include and finalize.

Best regards,
Don Myers

Bullboard Posts

The green resources stock scoring record quarterly growth